Pullamsetti, S.S.; Sitapara, R.; Osterhout, R.; Weiss, A.; Carter, L.L.; Zisman, L.S.; Schermuly, R.T.
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. Int. J. Mol. Sci. 2023, 24, 12653.
https://doi.org/10.3390/ijms241612653
AMA Style
Pullamsetti SS, Sitapara R, Osterhout R, Weiss A, Carter LL, Zisman LS, Schermuly RT.
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2023; 24(16):12653.
https://doi.org/10.3390/ijms241612653
Chicago/Turabian Style
Pullamsetti, Soni Savai, Ravikumar Sitapara, Robin Osterhout, Astrid Weiss, Laura L. Carter, Lawrence S. Zisman, and Ralph Theo Schermuly.
2023. "Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension" International Journal of Molecular Sciences 24, no. 16: 12653.
https://doi.org/10.3390/ijms241612653
APA Style
Pullamsetti, S. S., Sitapara, R., Osterhout, R., Weiss, A., Carter, L. L., Zisman, L. S., & Schermuly, R. T.
(2023). Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 24(16), 12653.
https://doi.org/10.3390/ijms241612653